We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
GSK always seems to fall hardest on the back of ftse decline. Only company to post positive news to off set this yet we take the biggest fall.
Should todays RNS push the share price up and further forward after this (interest rate Inflation rate) halt has settled down?
Do we have any key dates, for the next hearings. Any ideas when this will all be finalised ?
Sanofi settlements will undermine confidence. So far GSK has only set aside£40m for litigation costs,not settlements. It's possible that once word leaks out about the value of Sanofi's settlements, and it will leak with so many, that the generally touted figure of £5 billion will at £70,000 per case, may not be enough.
I think the problem is more to do with Zantac. Sanofies recent settlement hasn't helped at all inmv.
The sooner this is over the better. Delaware is the key here. Hopefully the worst case scenario is now factored into the share price. I.e. Five billion dollar settlement to clear this up.
I just hope that this doesn't turn into another gravy train for the us. Similar to BP and the gulf of Mexico disaster.
Down 8%+ in just over a week?? Can anyone shed any light on the reasons for this?
Mortgage renewal rate increase :(
The consensus forecast just published shows the sales growth expected for the top 9 GSK products by top analysts in 2024:
£m
Shingrix. 500
Arexvy. 372
Cabenuva. 339
Dovato. 332
Benlysta. 165
Apretude. 164
Nucala. 156
Ojjaara. 134
Jemperli. 128
Top 9. 2290
These products are also the biggest sales growth drivers in 2025 as well so achieving or exceeding the sales growth targets this year will be critical for the SP. In addition Camlipixant and Depemokimab are expected to launch in 2025 so pipeline progress on these assets this year will also be important for investor confidence.
Sorry Nick. waiting 2 months now. Hopefully just waiting a respectful amount of time before throwing the case in the bin.
The dividend is not likely to improve Chatroom - but by not holding you are missing the chance of a substantial re-rating when the Delaware ruling arrives. Even if it goes against GSK (which on balance it shouldn't) IMHO the worst case scenario is already priced in.
Not sure why GSK took such a hit compared with the other manufacturers of Ranitidine. It's like they are the only company to ever sell this drug.
Does anyone have a clue when Judge Medinilla's ruling is likely to be due?
I sold my shares earlier this the year because Im getting a far better div return on other stocks, GSK is currently only paying 3.44%. as of today rate.
I def intend to return later in the year if the div improves
Glaxo. Here is an extract from their 4th Quarter statement in late January this year :-
"The Board has declared a fourth interim dividend for 2023 of 16.00p per share (Q4 2022: 13.75p(3) per share).
Dividends remain an essential component of total shareholder return and GSK recognises the importance of
dividends to shareholders. On 23 June 2021, at the GSK Investor Update, GSK set out that from 2022 a progressive
dividend policy will be implemented guided by a 40 to 60 percent pay-out ratio through the investment cycle.
Consistent with this, and reflecting strong business performance during the year, GSK now expects to declare an
increased dividend of 16.00p for Q4 2023 and 58.00p per share for full year 2023. The expected dividend for 2024 is
60.00p. In setting its dividend policy, GSK considers the capital allocation priorities of the Group and its investment
strategy for growth alongside the sustainability of the dividend."
I personally think they will modestly exceed the 60p divided forecast for this year.
Haleon hav a policy of rising divi. Anyone know what gsk policy is, and ifit seems to be gently rising since the split, and likely to rise in future.. opinion only of course.
Why do they get picked on by NHS giving Salamol to asthma sufferers saying CFC free! Ventoline a long proven Glaxo medication with a good effective propellant that the feeble replacement does not have!
Tricky/old news, they are moving to Earnshaw St at the top of Oxford St
I can’t remember the last bad news here.
The Blenrep phase 3 DREAMM-8 trial met its primary endpoint of progression free survival with the regimen shown to significantly extend the time to disease progression or death versus the existing standard of care. The dataset has been unblinded early on the advice of its independent data monitoring committee. The readout comes just one month after GSK announced positive results from the DREAMM-7 trial. Armed with successes on two phase 3 trials GSK will be in discussion with the FDA about the reintroduction of the drug in the US.
Analysts at Citi anticipate risk adjusted Blenrep sales of £2.5bn in 2035.
No wonder GSK shares are up over 18% since the beginning of the year.
I'm hovering on the sell button TBH. Similar buy in average but need to shift a stack before an imminent mortgage renewal rate increase and the CGT reduction. A bird in the hand and all that.....
End of Tax year 23-24 on 05.04.24
HMRC are to reduce Capital Gains Tax allowance.
Why not rethink!!!
To break a blank posting day, when Glaxo has made a nice move up beyond £17 - gone well since my last purchase at £14 - have a below £13 average - not yet a high enough valuation to contemplate any sales.
GSK has sold GSK House in Brentford to Hadley Property Group.
Good news OR 'not'
I bought in at 13.28
More to go.
https://www.gsk.ai/
This should not have a negative impact on the SP in any way. GSK had the same results in the 2nd year. This was all about being first to Market which GSK was. People don’t like changing medication once something works for them. It’s then all about building on this by gaining approval for younger ages which GSK is also well ahead of the competition on.
It probably has to do with Pfizer's announcement from yesterday, threatening GSK's dominance so far here.
Pfizer says its RSV shot is protective through a second year
https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-says-its-rsv-shot-is-protective-through-second-year-2024-02-29/